The following is a summary of the Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript:
Financial Performance:
Pulse Biosciences reported cash and cash equivalents totaling $26.2 million as of June 30, 2024, compared to $58.7 million the previous year.
The company noted a total GAAP cost increase of $1.5 million to $11.7 million for Q2 2024, primarily driven by non-cash stock-based compensation.
Received $60 million in gross proceeds from a rights offering which closed in July 2024, not included in the reported cash balance.
Business Progress:
Completed first US soft tissue ablation cases under FDA clearance and received breakthrough device designation for a cardiac surgical system.
Expanded leadership team and moved headquarters to Miami, Florida.
Plans to initiate pivotal clinical trials for soft tissue ablation and a surgical system for atrial fibrillation in early 2025.
More details: Pulse Biosciences IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.